Cancer diagnostics News and Research

RSS

Hope for lung cancer patients

Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year. It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.

27 Oct 2009

New study provides insight into what women think on decision making with regard to breast cancer surgery

For women just diagnosed with breast cancer, one of the important decisions confronting them is whether to have a lumpectomy or mastectomy. A diagnosis of breast cancer will affect one in every eight women in the United States, according to the American Cancer Society, causing them to have to decide quickly about treatment.

27 Oct 2009

Physicians launch SUCCEED, program for breast cancer survivors

Breast cancer. A diagnosis of those two words elicits an array of emotions ranging from fear and anger, to confusion and uncertainty. To cope, women often look to family, friends and survivors for support, forming a network of people to help guide them through their diagnosis and treatment. As treatment begins, the plan seems clear.

27 Oct 2009

John Muir Health earns Network Cancer Program accreditation

John Muir Health’s Walnut Creek and Concord campuses have earned a three-year accreditation with commendation as a Network Cancer Program (NCP) from the American College of Surgeons Commission on Cancer (CoC), a consortium of professional organizations dedicated to improving survival and quality of life for cancer patients. John Muir Health is one of only two hospitals in California and the only one in the San Francisco Bay Area to receive the recognition.

24 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

NCI awards $2.8 million grant to Allegro Diagnostics

Allegro Diagnostics, a leader in the field of molecular diagnostics for lung cancer, has announced that its clinical study for BronchoGen(TM), a diagnostic test for patients suspected of having lung cancer, will receive up to $2.8 million in funding for a Phase I/II Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

22 Oct 2009

Biocare Medical on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation

Inc. magazine has ranked Biocare Medical No. 2984 on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation. The company's sales growth was 93.1% from 2005-2008.

22 Oct 2009

Herrick Foundation's $3M grant for cancer research

The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.

21 Oct 2009

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.

From Novo Nordisk 21 Oct 2009

Report: National investment on childhood and adolescent cancer research

The first-ever detailed examination of a country's investment in research on childhood and adolescent cancers was released today by the Canadian Cancer Research Alliance (CCRA) and the Canadian Partnership Against Cancer (the Partnership).

20 Oct 2009

Readmission of elderly patients after colectomy strongly linked with mortality: Study

Readmission to a hospital after standard surgical treatment for colon cancer is far more common than suspected for elderly patients according to researchers who presented their findings at the 2009 Clinical Congress of the American College of Surgeons. Results from the first study to determine nationwide readmission rates following colectomy [surgical removal of malignant disease and part of the colon] in the Medicare population revealed that nearly one in nine patients over the age of 65 was readmitted within 30 days.

19 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

Federal stimulus funds for comparative-effectiveness research in cancer

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

12 Oct 2009

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.

9 Oct 2009

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

Transgenomic, Inc. (OTC Bulletin Board: TBIO). The company announced today that it has licensed a high-sensitivity mutation detection technology called Cold-PCR from the Dana-Farber Cancer Institute (DFCI), Boston, MA.

9 Oct 2009

Specialists unanimously agree needle biopsy as 'best practice' for breast cancer diagnosis

A special report published in the October issue of the Journal of the American College of Surgeons indicates that an alarming 35% of initial diagnostic breast biopsies in the United States are still being done using unnecessary open surgical techniques. This in spite of the fact that it costs as much as three times more than the much less invasive and equally accurate needle biopsy technique.

8 Oct 2009

Cancer diagnostics News and Research

Hope for lung cancer patients

New study provides insight into what women think on decision making with regard to breast cancer surgery

Physicians launch SUCCEED, program for breast cancer survivors

John Muir Health earns Network Cancer Program accreditation

Early diagnostic for ovarian cancer to be developed

NCI awards $2.8 million grant to Allegro Diagnostics

Biocare Medical on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation

Herrick Foundation's $3M grant for cancer research

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Report: National investment on childhood and adolescent cancer research

Readmission of elderly patients after colectomy strongly linked with mortality: Study

Prometheus Laboratories introduces three new cancer diagnostic products

Federal stimulus funds for comparative-effectiveness research in cancer

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

Specialists unanimously agree needle biopsy as 'best practice' for breast cancer diagnosis

NHGRI awards Geospiza a SBIR grant to develop software systems for detecting rare mutations

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Premera Blue Cross supports cancer diagnostics study

$16 million federal stimulus funds for cancer research projects

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News